ESMO 2023 | Dr. Oliver Sartor: Lu-PSMA therapy could benefit mCRPC patients

ESMO 2023 | Dr. Oliver Sartor: Lu-PSMA therapy could benefit mCRPC patients

2023.11.06
Prostate cancer remains a significant health concern, especially in its metastatic castration-resistant form, which poses a formidable challenge for both patients and healthcare providers. Despite ongoing advancements in treatment options, the battle against this deadly disease continues. However, recent research has illuminated a ray of hope through the use of PSMA Lutetium therapy. In this article, we delve into the insights presented by Dr. Oliver Sartor at ESMO 2023 regarding the safety, efficacy, and potential benefits of PSMA Lutetium therapy in the treatment of metastatic castration-resistant prostate cancer.
ESMO 2023 |  Dr. Manuela Schmidinger: Research progress in the treatment of Renal cell carcinoma

ESMO 2023 |  Dr. Manuela Schmidinger: Research progress in the treatment of Renal cell carcinoma

2023.11.06
Renal cell carcinoma (RCC), a type of kidney cancer, has been the focus of extensive research in recent years. The recent advancements in the treatment of renal cell carcinoma have provided new hope for patients with this challenging disease.  As research continues, it is crucial to individualize treatment strategies based on patient risk profiles and explore novel approaches to address the specific needs of different RCC subtypes. Further research and clinical trials will undoubtedly continue to refine and expand our understanding of these groundbreaking therapies, with the ultimate goal of enhancing the quality of life and survival rates for individuals battling RCC.